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MicroRNAs (miRNAs) are short noncoding RNAs that regulate gene expression by binding to target mRNAs, which leads to
reduced protein synthesis and sometimes decreased steady-state mRNA levels. Although hundreds of miRNAs have been
identified, much less is known about their biological function. Several studies have provided evidence that miRNAs affect
pathways that are fundamental for metabolic control in higher organisms such as adipocyte and skeletal muscle differenti-
ation. Furthermore, some miRNAs have been implicated in lipid, amino acid, and glucose homeostasis. These studies open
the possibility that miRNAs may contribute to common metabolic diseases and point to novel therapeutic opportunities
based on targeting of miRNAs.MicroRNAs (miRNAs) are 19–22 nucleotide RNAs that regulate
gene expression posttranscriptionally by base pairing with com-
plementary sequences in the 30 untranslated regions (30UTRs) of
protein-coding transcripts. This interaction leads to translational
repression and, in many cases, to decreased mRNA levels
(Valencia-Sanchez et al., 2006). More than 300 human miRNAs,
many of them evolutionarily conserved, are currently listed in the
miRNA Registry version 7.1 (Griffiths-Jones, 2004). The total
number of miRNAs encoded in the human genome is currently
unclear. Computer-based predictions estimate that microRNAs
constitute as many as 2%–3% of all genes in the genome
(Berezikov et al., 2005). The function of most miRNAs is largely
unknown, but many miRNAs in invertebrates and vertebrates
are clearly involved in important cellular processes such as
differentiation and development (Alvarez-Garcia and Miska,
2005). It is estimated that up to one-third of all human genes
may be miRNA targets (Lewis et al., 2005).
Like conventional mRNAs, miRNAs are transcribed by RNA
polymerase II as long primary transcripts that are capped, poly-
adenylated, and spliced (Kim, 2005). The genomic localization of
many miRNAs overlaps with known protein coding or noncoding
genes (Rodriguez et al., 2004). These miRNAs share expression
patterns with their host-gene mRNA, thus indicating that they
are coordinately expressed. Furthermore, approximately 40%
of miRNAs are located in clusters that are <3.0 kb apart (Altuvia
et al., 2005). MicroRNAs are processed into 19–22 nt duplexes
by a two-step process involving nuclear and cytosolic RNase
III-type endonucleases, known as Drosha and Dicer, to yield
the ‘‘mature’’ miRNA. In a final step, this RNA duplex is loaded
into the RNA-induced silencing complex (RISC), one of the
strands is eliminated, and the remaining strand engages in
imperfect base pairing with specific sequences in their target
mRNAs.
The ability to control the rates of metabolic processes in
response to changes in the internal or external environment is in-
dispensable for all living cells. Mechanisms that are essential for
metabolic control and maintenance of homeostasis are complex
and involve transcriptional, translational, posttranslational, and
allosteric regulation. MiRNAs constitute a novel class of genes
that add a new level of regulation and fine tuning for geneCELL METABOLISM 4, 9–12, JULY 2006 ª2006 ELSEVIER INC. DOI 1expression that is likely to be important for a wide range of
cellular functions, including metabolism.
Although the function of most miRNAs is currently unknown,
several studies indicate that they may play important roles in di-
verse aspects of signaling and metabolic control. The earliest
phylogenetic evidence for a role of miRNA in responses to extra-
cellular stimuli comes from plants, where particular miRNAs
have been shown to accumulate in response to sulfur starvation,
abiotic stresses, or phytohormones (Jones-Rhoades et al.,
2006). For instance, several miRNAs have been identified as
influencing transcriptional regulators that are altered by auxin,
a phytohormone that plays critical roles during plant growth.
More recently, several intriguing studies have begun to shed
light on the role of miRNAs for metabolic control in invertebrates
and vertebrate animals.
Invertebrates
The first evidence for participation of miRNAs in metabolism
came from a forward genetic screen in the fruit fly Drosophila
melanogaster. Xu et al. (2003) found that loss of miR-14 doubled
the amount of total body triacylglycerides. Conversely, addi-
tional copies of miR-14 in the fly genome decreased triacylgly-
ceride levels. The mechanism for this effect is unknown. Using
a similar screening method, Teleman and Cohen (2006) more
recently identified a role for miR-278 in energy homeostasis of
Drosophila. MiR-278 is prominently expressed in the fat body
of flies, and homozygous mutations for miR-278 have a smaller
fat body and reduced ratio of total body triglycerides to total pro-
tein. This phenotype could be rescued by miR-278 expression.
Mutant flies also exhibited hyperglycemia in spite of elevated
insulin-like peptide levels. The authors conclude that miR-278
regulates insulin sensitivity through its target, the membrane-
associated protein expanded. These two studies point to an
important role for miRNAs in fat tissue of Drosophila. Work by
Sokol and Ambros (2005) demonstrated that miR-1, one of the
most highly conserved miRNAs in the animal kingdom, is also
essential for proper skeletal muscle function in the fruit fly.
Loss-of-function of muscle-specific miR-1 in Drosophila results
in small, immobilized larvae with severely deformed muscula-
ture. The lethality of these mutants can be rescued when0.1016/j.cmet.2006.05.009 9
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and muscle. Interestingly, feeding triggers DmiR-1KO-associ-
ated paralysis and death in DmiR-1KO flies, a phenotype that
can be prevented when DmiR-1KO larvae are starved. These
results indicate that DmiR-1 is not required for the formation
or physiological function of the larval musculature but is essen-
tial for postmitotic growth of larval muscle. The target genes of
miR-1 that mediate this effect are unknown. The high evolution-
ary conservation of miR-1 suggests that miR-1 could also be
important for adaptation of vertebrate skeletal muscle to envi-
ronmental challenges.
In another invertebrate organism,Caenorhabditis elegans, the
miRNA lin-4 has been found to be critical in development.
Recently, it was shown that lin-4 also regulates life span in this
organism (Boehm and Slack, 2005). Animals with loss-of-func-
tion mutation in lin-4 displayed a life span that was significantly
shorter than that of the wild-type. In contrast, overexpression of
lin-4 led to a lengthened life span. Lin-4 binds with imperfect
complementarity to the 30UTR of its target, lin-14, to prevent
its translation. Consistent with this data, mutations in lin-14
exhibited longevity. Interestingly, life-span extension conferred
by a reduction in lin-14 was dependent on the forkhead tran-
scription factor daf16, which is known to regulate life span
through insulin-PI3 kinase-Akt signaling. It is intriguing that the
closest daf-16 homologs in mammals are the transcription
factors Foxo1 and Foxa2, both of which are regulated by insulin
signaling and play important roles in glucose and lipid homeo-
stasis (Puigserver et al., 2003; Wolfrum et al., 2004). While the
exact mechanism of the extended-life-span phenotype remains
to be determined, the data provide an example of gene-regula-
tion crosstalk of miRNAs and insulin signaling. Thus, the above
summarized studies provide persuasive evidence that connects
miRNA function and metabolism in invertebrates. However, it is
worth noticing that, with the exception of miR-1, the analyzed
miRNAs are not conserved in vertebrates. Thus, these results
cannot directly be related to mammalian and human tissues.
However, it is still possible that miR-14 and miR-278 regulate
the expression of evolutionarily conserved target genes that
may shed light on novel pathways affecting insulin signaling
and energy homeostasis.
Vertebrates
The first evidence for a role of miRNAs in hormone secretion in
vertebrates came from an unbiased cloning approach of small
RNAs from the pancreatic b cell line MIN6 (Poy et al., 2004).
This approach identified 11 novel miRNA sequences, among
them two pancreatic-islet-enriched miRNAs, miR-375 and
miR-376. Overexpression of miR-375 decreased insulin secre-
tion, while inhibiting miR-375 function increased insulin release
from pancreatic b cells. Although the precise mechanism for
the negative regulation of insulin secretion by miR-375 is not
understood, this miRNA seems to inhibit the exocytosis process
of insulin-secretory granules, possibly through SNARE proteins
(e.g., Vti-1a) and myotrophin, two predicted and experimentally
validated target genes of miR-375. Future studies of mutant
mice with genetic miR-375 deletions will be able to address
whether this miRNA also affects pancreatic b cell proliferation,
differentiation, and survival.
There is also emerging evidence that miRNAs might play
a role in differentiation of insulin-sensitive organs such as the
adipocyte and muscle. Esau et al. (2004) inhibited the activity10of 86 miRNAs in primary human preadipocytes with 20-O-me-
thoxyethyl (20-O-MOE) phosphorothioate-modified antisense
RNA oligonucleotides (ASO) by transfection prior to induction
of differentiation. They found that two ASOs targeting miR-9*
and miR-143 inhibited the differentiation process as assessed
by a reduction in triglyceride accumulation and decreased
expression of adipocyte-specific genes. Furthermore, miR-143
expression levels were found to be higher in adipocytes than
in preadipocytes. In muscle, miRNAs have been implicated in
myoblast differentiation. MiR-1 and miR-133 are transcribed
from a common polycistronic gene in a tissue-specific manner
during development (Chen et al., 2006). However, they have
opposite roles in modulating skeletal muscle proliferation and
differentiation in cultured myoblasts in vitro and in Xenopus lae-
vis embryos. MiR-1 promotes myogenesis by targeting histone
deacetylase 4 (HDAC4), a transcriptional repressor of muscle
gene expression. In contrast, miR-133 enhances myoblast pro-
liferation by repressing the serum response factor (SRF). These
data demonstrate that miRNAs can carry out distinct biological
functions even when they derive from a common precursor. The
skeletal muscle phenotype is controlled not only by miR-1 and
miR-133 but also by miR-181. Mir-181 is strongly upregulated
during differentiation of embryonic stem cells and myoblast
cell lines and is required for this process, partly through inhibi-
tion of its target Hox-A11, an inhibitor of MyoD (Naguibneva
et al., 2006). Interestingly, SRF and MyoD itself are transcrip-
tional regulators of miR-1 (Zhao et al., 2005). Together, these
findings add to the complexity of coordinated gene expression
and transcriptional circuits that control skeletal muscle gene
expression during development and possibly regeneration
(Figure 1).
Several lines of evidence indicate that miRNAs may also reg-
ulate pathways in amino acid metabolism. Mersey et al. (2005)
showed that the vertebrate miR-29b controls the amount of
the branched-chain a-ketoacid dehydrogenase (BCKD) com-
plex in mammalian cells, which catalyzes the first irreversible
step in branched-chain amino acid (BCAA) catabolism. The
BCAAs leucine, isoleucine, and valine are amino acid compo-
nents in almost all proteins and in addition play important roles
in nitrogen metabolism, e.g., the synthesis of glutamine and al-
anine. Furthermore, leucine can stimulate protein synthesis and
act as a stimulus for insulin secretion. MiR-29b targets a compo-
nent of the BCKD complex in HEK293 cells and thus inhibits its
activity. Cellular BCKD activity is also tightly regulated by allo-
steric and covalent mechanisms. The work of Mersey et al. is
an intriguing example of how a miRNA can add another level
of regulation for a metabolically significant enzyme. An involve-
ment of miRNAs in the regulation of amino acid metabolism has
also been suggested in flies, where bioinformatic approaches
have predicted several enzymes to be targets of miR-277 (Stark
et al., 2003).
Recent technical advances to silence miRNAs in mice using
RNA analogs have generated further evidence for a role of
miRNAs in metabolism. The predominant miRNA in the liver,
miR-122, has been shown to regulate cholesterol and lipid
homeostasis in two independent studies. This miRNA is abun-
dantly expressed in human and rodent liver tissue, with esti-
mates ranging from 50,000 to 80,000 copies per cell. Using
a new class of miRNA inhibitors, termed antagomirs, Krutzfeldt
et al. (2005) studied the effect of miR-122 on glucose and
lipid metabolism in mice. Antagomir-122 induced efficientCELL METABOLISM : JULY 2006
M I N I R E V I E WFigure 1. Regulation of metabolic pathways by microRNAs in invertebrates and vertebrates
The schematic illustration summarizes the current evidence from the literature for the function of miRNAs in metabolism of different tissues.degradation of miR-122 in the liver and led to a significant de-
crease in plasma cholesterol levels after 4 days of treatment.
In this study, no changes in glucose or triglyceride levels were
measured compared to controls. Microarray expression analy-
sis of livers that lack miR-122 demonstrated that a cluster of
cholesterol-biosynthesis genes, including HMG-CoA reductase,
the rate-limiting step of cholesterol synthesis, was reduced
compared to control livers, a finding that could contribute to
the reduced plasma cholesterol levels. Esau et al. (2006)
extended these results by using a different class of miRNA inhib-
itors (ASOs) and a longer treatment protocol. After 4 weeks,
ASO-122-treated mice exhibited decreased cholesterol and tri-
glyceride levels without changes in plasma glucose concentra-
tions. Isolated hepatocytes of treated mice exhibited decreased
hepatic fatty-acid synthesis and sterol synthesis as well as in-
creased fatty-acid oxidation. Furthermore, levels of activated
AMP-activated kinase (AMPK) were increasedz2.5-fold. Acti-
vation of AMPK is of interest since this kinase can inhibit the
activity of key enzymes of fatty-acid synthesis and cholesterolCELL METABOLISM : JULY 2006synthesis (Kahn et al., 2005) and might therefore play a role in
the observed effects. Interestingly, a 5.5-week treatment of
mice with high-fat diet not only reduced plasma cholesterol lev-
els but also improved liver steatosis. The target genes of miR-
122 that regulate hepatic and plasma lipid levels are currently
unknown. The correlation between inhibition of miR-122 and
the downregulation of genes, e.g., genes involved in cholesterol
synthesis, suggests that miR-122 may negatively regulate a tran-
scriptional repressor.
Numerous studies in past years have conclusively demon-
strated that miRNAs are regulators of important biological
processes, including cellular differentiation, proliferation, and
developmental timing. The studies summarized here suggest
that miRNAs are also regulators of a broad range of metabolic
pathways. Until recently, the primary focus of investigators
studying mammalian miRNAs has been to identify and catalog
the complete miRNA inventory and its expression pattern using
cloning, bioinformatics, and gene-expression approaches.
Now, more studies can be anticipated that will focus on the11
M I N I R E V I E Welucidation of miRNA function, for example on their role in me-
tabolism. Furthermore, genetic studies will shed light on
whether variations in miRNA genes or their respective targets
can predispose to common metabolic diseases. These studies
will finally reveal whether miRNAs are viable targets for RNA
therapeutics to treat metabolic diseases.
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